SCHEMBL4010523

SCHEMBL4010523

Cc1cccc(C(=O)NCN2CCC(c3cccc[n+]3[O-])CC2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 19/20 1.00
DRD2 P14416 2/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4005324 0.92 DRD4 (1.00) DRD4
SCHEMBL4006645 0.88 DRD4 (1.00) DRD4
SCHEMBL4005017 0.88 DRD4 (1.00) DRD4
SCHEMBL4008867 0.86 DRD4 (0.87) DRD4
SCHEMBL4004185 0.85 DRD4 (1.00) DRD4
SCHEMBL4005467 0.85 DRD4 (0.74) DRD4
SCHEMBL4003579 0.85 DRD4 (1.00) DRD4
SCHEMBL4005079 0.85 DRD4 (0.84) DRD4
SCHEMBL4006661 0.85 DRD4 (1.00) DRD4
SCHEMBL4006357 0.85 DRD4 (1.00) DRD4DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7528134-B2 Acetamides and benzamides that are useful in treating sexual dysfunction ABBOTT LABORATORIES INC. (US) 2009-05-05 US claimed
EP-1509213-A2 ACETAMIDES AND BENZAMIDES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION Abbott Laboratories (US) 2005-03-02 EP claimed
US-20040029887-A1 Acetamides and benzamides that are useful in treating sexual dysfunction ABBOTT LABORATORIES 2004-02-12 US claimed
US-20030229094-A1 Acetamides and benzamides that are useful in treating sexual dysfunction ABBOTT LABORATORIES 2003-12-11 US claimed
WO-2003099266-A2 ACETAMIDES AND BENZAMIDES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION ABBOTT LABORATORIES (US) 2003-12-04 WO claimed
CN-122010873-A Synthesis method of gem-diamine compound 合肥工业大学 2026-05-12 CN disclosed
EP-4079311-B1 NMN AND DERIVATIVES FOR USE IN THE TREATMENT OF DEPRESSION AND/OR ANXIETY IN PATIENTS HAVING A FORM OF PARKINSONISM NUVAMID SA (CH) 2025-10-01 EP disclosed
US-12201628-B2 Neuronal modulation TECHNION RESEARCH &DEVELOPMENT FOUNDATION LIMITED (IL) 2025-01-21 US disclosed
US-20240417421-A1 NMN And Derivatives For Its Use In The Treatment Of Depression And/Or Anxiety In Patients Having A Form Of Parkinsonism NUVAMID SA (CH) 2024-12-19 US disclosed
US-20240366627-A1 SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2024-11-07 US disclosed
US-20240352484-A1 REWARD SYSTEM ACTIVATION FOR THERAPEUTIC PURPOSES TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) 2024-10-24 US disclosed
US-11963964-B2 Small molecules for mouse satellite cell proliferation PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2024-04-23 US disclosed
US-20120115879-A1 METHOD OF TREATMENT FOR MENTAL DISORDERS Sumitomo Pharma Co., Ltd. (JP) 2012-05-10 US disclosed
US-7528134-B2 Acetamides and benzamides that are useful in treating sexual dysfunction ABBOTT LABORATORIES INC. (US) 2009-05-05 US disclosed
US-20060009461-A1 Acetamides and benzamides that are useful in treating sexual dysfunction BHATIA PRAMILA A 2006-01-12 US disclosed
EP-1509213-A2 ACETAMIDES AND BENZAMIDES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION Abbott Laboratories (US) 2005-03-02 EP disclosed
US-20040029887-A1 Acetamides and benzamides that are useful in treating sexual dysfunction ABBOTT LABORATORIES 2004-02-12 US disclosed
US-20030232836-A1 Acetamides and benzamides that are useful in treating sexual dysfunction ABBOTT LABORATORIES 2003-12-18 US disclosed
US-20030229094-A1 Acetamides and benzamides that are useful in treating sexual dysfunction ABBOTT LABORATORIES 2003-12-11 US disclosed
WO-2003099266-A2 ACETAMIDES AND BENZAMIDES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION ABBOTT LABORATORIES (US) 2003-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229094-A1 Acetamides and benzamides that are useful in treating sexual dysfunction CATSPER1, CYP19A1, PDE12 DRD4 1497/4885DRD2 1644/4885
US-20040029887-A1 Acetamides and benzamides that are useful in treating sexual dysfunction CATSPER1, CYP19A1, PDE12 DRD4 1497/4885DRD2 1644/4885
US-20060009461-A1 Acetamides and benzamides that are useful in treating sexual dysfunction PDE12, NAAA, CYP19A1 DRD4 1334/4885DRD2 1439/4885
US-20120115879-A1 METHOD OF TREATMENT FOR MENTAL DISORDERS DRD4, HTR4, SLC6A3 DRD4 1/4885DRD2 6/4885
US-20240366627-A1 SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION MKI67, MYLK2, MYH2 DRD4 4729/4885DRD2 4820/4885
US-11963964-B2 Small molecules for mouse satellite cell proliferation MKI67, MYLK2, MYH2 DRD4 4729/4885DRD2 4820/4885
US-20030232836-A1 Acetamides and benzamides that are useful in treating sexual dysfunction CATSPER1, CYP19A1, PDE12 DRD4 1497/4885DRD2 1644/4885
US-20240417421-A1 NMN And Derivatives For Its Use In The Treatment Of Depression And/Or Anxiety In Patients Having A Form Of Parkinsonism SNCA, NLN, PARK7 DRD4 544/4885DRD2 576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.